OBJECTIVE: We investigated the expression and clinical significance of Cancerous inhibitor of protein phosphatase 2A (CIP2A) in Cutaneous malignant melanoma (CMM). METHODS: CIP2A expression was analyzed by immunohistochemistry and western blot. We tested the invasion and migration capability of A375 cells with Matrigel invasion assay, Scratch migration assay and Matrigel migration assay after down-regulating CIP2A expression using siRNA. RESULTS: CIP2A immunostaining level was correlated with Breslow thickness, Clark's Level and lymphovascular invasion. High-CIP2A expression implied poor survival for patients. Downregulation of CIP2A attenuated metastasis of CMM cells. CONCLUSIONS: CIP2A may serve as a novel marker to predict the prognosis for CMM patients.
OBJECTIVE: We investigated the expression and clinical significance of Cancerous inhibitor of protein phosphatase 2A (CIP2A) in Cutaneous malignant melanoma (CMM). METHODS:CIP2A expression was analyzed by immunohistochemistry and western blot. We tested the invasion and migration capability of A375 cells with Matrigel invasion assay, Scratch migration assay and Matrigel migration assay after down-regulating CIP2A expression using siRNA. RESULTS:CIP2A immunostaining level was correlated with Breslow thickness, Clark's Level and lymphovascular invasion. High-CIP2A expression implied poor survival for patients. Downregulation of CIP2A attenuated metastasis of CMM cells. CONCLUSIONS:CIP2A may serve as a novel marker to predict the prognosis for CMM patients.
Authors: Vivi Ann Flørenes; Elisabeth Emilsen; Hiep Phuc Dong; Mette Førsund; Ruth Holm; Ana Slipicevic Journal: Cancer Med Date: 2015-02-07 Impact factor: 4.452